Nanogen, Inc. (Nasdaq: NGEN), producer of the only commercially available system for electronically controlled DNA reactions on microchips, is presenting its progress in developing electronically enabled technologies for the high-throughput screening (HTS) of drug candidates acting on protein kinases and potentially a wide variety of other enzymes. These electronic, fluorescent assays are free of antibodies and have the potential to improve the cost and quality of the screening process. Nanogens progress was presented at the Screentech 2001 Conference on March 12-16, 2001, and will also be the subject of a lecture at the Discovery 2001 show in San Diego on March 27, 2001. The electronic approaches demonstrated by Nanogen encompass microtiter-plate and MEMS applications and are designed with the intent of integrating Nanogens technology with current high-throughput screening processes. Nanogen also revealed a combinatorial-chemistry approach for the identification of specific substrates for novel kinases emerging from the recently sequenced human genome. Combining specific substrate-identification tools with the electronic assays is expected to significantly aid drug discovery for a wide range of enzyme targets.
Protein kinases are widely used by drug development organizations such as pharmaceutical and biotechnology companies as attractive drug targets. Through DNA sequence analysis, it is known that there are approximately 800 protein kinases in the human genome. Furthermore, it is presently estimated that over 10% of cellular proteins are subject to covalent modification via phosphorylation. Protein kinases are particularly important in signal transduction pathways, and kinase dysfunction is thought to contribute to many forms of cancer.
At Screentech 2001, Nanogen presented its progress towards developing different formats of electronic HTS technology for protein-kinase analyses. The formats involve electronic HTS plates, which signifi
Contact: Laura Hansen